Format

Send to

Choose Destination
Int J Cancer. 2004 May 20;110(1):3-14.

Inhaled particles and lung cancer, part B: paradigms and risk assessment.

Author information

1
Particle Research, Institut für Umweltmedizinische Forschung, Heinrich-Heine-University Düsseldorf, Auf'm Hennekamp 50, D-40225 Düsseldorf, Germany. paul.borm@uni-duesseldorf.de

Abstract

Poorly soluble particles of low toxicity (PSP), such as CB, TiO(2) and coal mine dust, have been demonstrated to cause lung cancer in rodents, being most pronounced in rats. Adequate epidemiologic studies do not clearly indicate increased lung cancer rates in humans exposed to such particles. This has caused controversial positions in regulatory decisions on PSP on different levels. The present review discusses the current paradigms in rodent particle carcinogenicity, i.e., (i) role of particle overload and of persistent inflammation and (ii) fibrosis as an intermediate step in particle-induced lung cancer with regard to human risk assessment. Fibrosis, which is usually considered a precursor of lung cancer in humans, was not related to lung tumors in an animal study using 6 different particles, each at 3 dosages. Lung tumors after both inhalation and intratracheal instillation of PSP are related to particle surface dose, which forwards hazard assessment at surface-based nonoverload concentrations and a standard setting using surface as an exposure metric. The scarce data available on humans do not support the overload concept but suggest a role for persistent lung inflammation. Differences in antioxidant protection between different rodent species correlate with susceptibility to PSP-induced carcinogenicity and support the need for detailed studies on antioxidant response in humans. Apart from such bridging studies, further focus is also needed on surface chemistry and modifications in relation to their adverse biologic effects.

PMID:
15054863
DOI:
10.1002/ijc.20064
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center